vidarabine has been researched along with Disease Exacerbation in 120 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (4.17) | 18.2507 |
| 2000's | 64 (53.33) | 29.6817 |
| 2010's | 48 (40.00) | 24.3611 |
| 2020's | 3 (2.50) | 2.80 |
| Authors | Studies |
|---|---|
| Beelen, D; Bethge, W; Blaise, D; Chevallier, P; Ciceri, F; de Witte, T; Ganser, A; Iacobelli, S; Koster, L; Kröger, N; Luft, T; Mufti, GJ; Nagler, A; Robin, M; Schwerdtfeger, R; Shimoni, A; Volin, L; Yakoub-Agha, I | 1 |
| Abrams, ZB; Abruzzo, LV; Bahlo, J; Barron, LL; Benner, A; Bloehdorn, J; Bondaruk, JE; Coombes, KR; Czerniak, BA; Ferrajoli, A; Fischer, K; Hallek, M; Herling, CD; Keating, MJ; Majewski, T; Oakes, CC; Stilgenbauer, S | 1 |
| Anagnostopoulos, A; Bhoi, S; Duran-Ferrer, M; Ghia, P; Kollia, P; Ljungström, V; Malousi, A; Mansouri, L; Martin-Subero, JI; Moysiadis, T; Oscier, D; Papakonstantinou, N; Plevova, K; Pospisilova, S; Pott, C; Queirós, AC; Ritgen, M; Rosenquist, R; Stamatopoulos, K; Stavroyianni, N; Trentin, L; Tsagiopoulou, M | 1 |
| Fukuhara, S; Izutsu, K; Kinoshita, T; Ohashi, Y; Suzumiya, J; Takizawa, J; Tobinai, K; Yamamoto, G | 1 |
| Campbell, TB; Jagannath, S; Madduri, D; Neumann, F; Parekh, S; Petrocca, F | 1 |
| Chen, BA; Ding, JH; Ge, Z; Sun, AN; Wu, DP; Yu, ZP | 1 |
| Abuelgasim, KA; Al Atwi, N; Al Balwi, M; Almughairi, A; Alshieban, S; Alsubaie, M; Rehan, H | 1 |
| Bancaud, A; Bradbury, A; Cazaux, C; Filleron, T; Fournié, JJ; Gilhodes, J; Grgurevic, S; Hoffmann, JS; Laurent, G; Montilla-Perez, P; Pelofy, S; Queille, S; Quillet-Mary, A; Récher, C; Ysebaert, L | 1 |
| Bakala, J; Declercq, H; Delette, C; Drumez, E; Duhamel, A; Guidez, S; Hivert, B; Labreuche, J; Marolleau, JP; Morel, P; Protin, C; Verlay, M; Ysebaert, L | 1 |
| Chen, K; Feng, Z; Li, X; Lin, J; Pan, X; Qi, W; Yan, Y | 1 |
| Böttcher, S; Bühler, A; Busch, R; Döhner, H; Eichhorst, B; Fingerle-Rowson, G; Fink, AM; Fischer, K; Hallek, M; Hensel, M; Hopfinger, G; Kneba, M; Mayer, J; Pflug, N; Ritgen, M; Staib, P; Stilgenbauer, S; Wendtner, CM; Wenger, M; Winkler, D; Zenz, T | 1 |
| Badoux, X; Jones, JA; Kantarjian, H; Keating, MJ; Kipps, TJ; O'Brien, S; Plunkett, W; Tsimberidou, AM; Wen, S; Wierda, WG | 1 |
| Blaise, D; Castagna, L; Chabannon, C; Crocchiolo, R; El-Cheikh, J; Faucher, C; Furst, S; Granata, A; Lemarie, C; Oudin, C; Saillard, C; Signori, A | 1 |
| Choi, I; Jang, YJ; Jeon, M; Jung, SJ; Kang, M; Kang, YA; Kim, DY; Kim, H; Kim, HJ; Lee, JH; Lee, JL; Lee, KH; Lee, YS; Park, SY; Seol, M; Yeom, YI; Yoon, SR; Yun, SC | 1 |
| Imamura, Y | 1 |
| Afrough, A; Hamdi, A; Hosing, CM; Lu, G; Muzzafar, T; Popat, UR; Qazilbash, MH | 1 |
| Advani, RH; Anderson, KC; Barlogie, B; Dimopoulos, MA; García-Sanz, R; Gertz, MA; Ghobrial, IM; Gregory, SA; Kastritis, E; Kimby, E; Kyle, RA; Kyriakou, C; Landgren, O; Leblond, V; Leleu, X; Maloney, D; Merlini, G; Morel, P; Morra, E; Munshi, N; Owen, RG; Rummel, M; Terpos, E; Thomas, SK; Treon, SP | 1 |
| Chen-Liang, TH; Florensa, L; Jerez, A; Ortuño, FJ | 1 |
| Cortes, J; Do, KA; Ferrajoli, A; Kantarjian, H; Keating, MJ; Khouri, I; Lerner, S; O'Brien, S; Plunkett, W; Tam, CS; Wang, X; Wierda, W | 1 |
| Byrd, JC; Gordon, A; Guinn, D; Hertlein, E; Jaglowski, S; Johnson, AJ; Larson, R; Lin, TS; Maddocks, K; Marcucci, G; Ruppert, AS; Woyach, J | 1 |
| Streu, E | 1 |
| Beck, C; Dreyfus, B; Dyer, MJ; Gupta, IV; Hellman, A; Hess, G; Hillmen, P; Jewell, RC; Kozlowski, P; Lisby, S; Mayer, J; Nebot, N; Österborg, A; Pfreundschuh, M; Phillips, JL; Rizzi, R; Schetelig, J; Schuh, A; Smolej, L; Spacek, M; Wierda, WG; Williams, V | 1 |
| Brown, JR; Fisher, DC; Freedman, AS; Mikler, E; Neuberg, D; Reynolds, HM; Takebe, N; Tesar, B; Thompson, C; Werner, L; Yu, L | 1 |
| Estrov, Z; Faderl, S; Ferrajoli, A; Keating, MJ; O'Brien, SM; Short, NJ; Smith, SC; Wierda, WG | 1 |
| Broers, AE; Janssen, JJ; Raymakers, R; Slot, S; Smits, K; Te Boekhorst, PA; van de Donk, NW; Witte, BI; Zweegman, S | 1 |
| Catovsky, D; Else, M; Oscier, D; Wade, R | 1 |
| Zhang, L; Zou, W | 1 |
| Chadwick, H; Counsell, N; Evans, K; Johnson, RJ; Pottinger, BT; Rudin, CE; Smith, P; Townsend, W; Wickham, C | 1 |
| Chen, P; Chen, X; Chen, Z; Hu, J; Hua, X; Le, S; Li, J; Lin, Q; Liu, T; Luo, X; Ren, J; Yang, T; Yuan, X; Zhang, L; Zheng, H; Zheng, J; Zheng, X; Zheng, Z | 1 |
| Bole, J; Castro, JE; Kipps, TJ; Rassenti, L; Sandoval-Sus, JD | 1 |
| Baldanti, F; Citro, A; Gatti, M; Lazzarino, M; Orlandi, EM; Pochintesta, L | 1 |
| Badawi, N; Jones, CA; Walker, KS | 1 |
| Alatrash, G; Albitar, M; Burger, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Kantarjian, HM; Keating, MJ; Lerner, S; Manshouri, T; O'Brien, S; Wang, X; Wierda, WG | 1 |
| Andreadis, C; Kanetsky, PA; Nasta, SD; Olin, RL; Schuster, SJ; Ten Have, TR | 1 |
| Bojarska-Junak, A; Chocholska, S; Dmoszynska, A; Klimek, P; Kowal, M; Podhorecka, M | 1 |
| Acholonu, S; Champlin, R; Dabaja, B; Donato, M; Duvic, M; Hosing, C; Khouri, I; Richmond, H; Singh, L; Wei, W | 1 |
| Golubeva, ME; Isaeva, NV; Kudriavtseva, AV; Malykh, OV; Tkachenko, SB; Zagoskina, TP | 1 |
| Keating, MJ; Tam, CS | 1 |
| Cao, X; Dong, HJ; Fang, C; Hong, M; Li, JY; Miao, KR; Wang, DM; Xu, W; Zhu, DX | 1 |
| Hillmen, P | 1 |
| Bergmann, M; Berrebi, A; Böttcher, S; Bühler, A; Busch, R; Caligaris-Cappio, F; Catalano, J; Cazin, B; Döhner, H; Eichhorst, BF; Fingerle-Rowson, G; Fink, AM; Fischer, K; Hallek, M; Hensel, M; Hess, G; Hopfinger, G; Jäger, U; Kneba, M; Mayer, J; Mendila, M; Ritgen, M; Seymour, JF; Staib, P; Stilgenbauer, S; Trneny, M; von Grünhagen, U; Wendtner, CM; Westermann, A; Winkler, D; Zenz, T; Zinzani, PL | 1 |
| Lech-Maranda, E; Robak, P; Robak, T | 1 |
| Chen, R; Delioukina, M; Forman, S; Kogut, N; Nademanee, A; Palmer, JM; Popplewell, L; Rosenthal, J; Shen, J; Smith, E | 1 |
| Freedman, AS; Sweetenham, JW | 1 |
| Hivert, B; Leblond, V; Morel, P; Tamburini, J; Tournilhac, O; Vekhoff, A | 1 |
| Bertoni, F; Bruscaggin, A; Cerri, M; Chiaretti, S; Cresta, S; Dalla-Favera, R; Deaglio, S; Deambrogi, C; Del Giudice, I; Fangazio, M; Foà, R; Forconi, F; Gaidano, G; Gargiulo, E; Gattei, V; Guarini, A; Khiabanian, H; Messina, M; Monti, S; Pasqualucci, L; Rabadan, R; Rasi, S; Rossi, D; Spina, V; Vaisitti, T | 1 |
| Agura, E; Bethge, W; Blume, KG; Bruno, B; Chauncey, TR; Franke, GN; Georges, GE; Hari, P; Hübel, K; Langston, A; Laport, GG; Maloney, DG; Maris, MB; Maziarz, RT; McSweeney, PA; Mielcarek, M; Niederwieser, D; Petersen, FB; Pulsipher, MA; Sahebi, F; Sandmaier, BM; Sorror, ML; Storb, R; Storer, BE; Vindeløv, L; Yeager, A | 1 |
| Böttcher, S; Bühler, A; Busch, RM; Döhner, H; Eichhorst, BF; Fingerle-Rowson, G; Fink, AM; Fischer, K; Hallek, MJ; Kneba, M; Mendila, M; Ritgen, M; Stilgenbauer, S; Wendtner, CM; Wenger, MK; Zenz, T | 1 |
| Han, W; Wei, Z; Yanxia, Y; Ying, X; Yuhua, J | 1 |
| Brychtova, Y; Chovancova, J; Doubek, M; Francova, HS; Horky, O; Krejci, M; Mayer, J; Navratil, M; Pospisilova, S; Stehlikova, O; Tichy, B; Tomiska, M | 1 |
| Hanzis, C; Hunter, ZR; Ioakimidis, L; Manning, RJ; Patterson, CJ; Sheehy, P; Treon, SP; Tripsas, C; Turnbull, B | 1 |
| Ahmed, G; Davis, Z; Dyer, M; Gonzalez, D; Matutes, E; Moss, P; Oldreive, C; Oscier, D; Parker, A; Richards, S; Skowronska, A; Stankovic, T; Taylor, AM; Thomas, P | 1 |
| Brannagan, TH; Leitch, MM; Sherman, WH | 1 |
| McCormack, C; McCurdy, O; Prince, HM; Ritchie, D | 1 |
| Arcache, J; Arnaud, P; Berger, F; Callet-Bauchu, E; Coiffier, B; Dumontet, C; Felman, P; Hequet, O; Salles, G; Thieblemont, C | 1 |
| Champlin, RE; Keating, MJ; Khouri, IF; Saliba, RM | 1 |
| de Fabritiis, P; De Propris, MS; Foa, R; Gentile, M; Giammartini, E; Giannarelli, D; Mandelli, F; Mauro, FR; Meloni, G; Rapanotti, MC | 1 |
| Carella, A; de Elvira, CR; Goldstone, AH; Mackinnon, S; Robinson, SP; Russell, N; Schmitz, N; Taghipour, G | 1 |
| Baker, LH; Bekele, BN; Benjamin, RS; Champlin, RE; Thall, PF; Wathen, JK | 1 |
| Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P | 1 |
| Paschal, BR | 1 |
| Anagnostopoulos, N; Dimopoulos, MA; Efstathiou, E; Gika, D; Grigoraki, V; Hamilos, G; Matsouka, C; Mitsibounas, D; Papadimitriou, C; Siapkaras, I | 1 |
| Bardou, VJ; Bay, JO; Bilger, K; Blaise, D; Boiron, JM; Braud, AC; Cahn, JY; Chabannon, C; Choufi, B; Faucher, C; Fleury, J; François, S; Gratecos, N; Gravis, G; Maraninchi, D; Michallet, M; Mohty, M; Sotto, JJ; Viens, P; Viret, F | 1 |
| Bentley, P; Fegan, C; Hooper, L; Hoy, T; Milligan, D; Pepper, C; Pratt, G; Starczynski, J; Thomas, A | 1 |
| Beyer, J; Claviez, A; Dörffel, W; Dreger, P; Ehninger, G; Klingebiel, T; Nürnberger, W; Schmitz, N; Suttorp, M | 1 |
| Lokhorst, HL; Petersen, EJ; Verdonck, LF | 1 |
| Baccarani, M; Fanin, R; Gentile, M; Mandelli, F; Marin, L; Mauro, FR; Stefoni, V; Tura, S; Vegna, ML; Zaja, F; Zinzani, P | 1 |
| Barry, T; Ben Alon, D; Ben Dor, D; Blumental, R; Ducach, A; Lugassy, G; Nemets, A | 1 |
| Bucher, C; Buser, AS; Gratwohl, A; Heim, D; Passweg, JR; Tichelli, A | 1 |
| Appelbaum, FR; Byrd, JC; Hines, JD; Kolitz, JE; Larson, RA; Morrison, VA; Peterson, BL; Rai, K; Schiffer, CA; Shepherd, L | 1 |
| Disel, U; Ergin, M; Paydas, S; Yavuz, S | 1 |
| Andreeff, M; Beran, M; Ferrajoli, A; Giles, FJ; Kantarjian, HM; Keating, MJ; Lerner, S; O'Brien, S; Tsimberidou, AM; Wierda, WG | 1 |
| Baker, JE; Baron, F; Blume, KG; Chauncey, TR; Gooley, TA; Grumet, FC; Heimfeld, S; Little, MT; Maloney, DG; Maris, MB; Oparin, D; Radich, JP; Sandmaier, BM; Storb, R; Zellmer, E | 1 |
| Majumdar, G; Ramachandran, A | 1 |
| Amadori, S; Bruno, A; Buccisano, F; Cox, MC; Degan, M; Del Poeta, G; Del Principe, MI; Gattei, V; Marini, R; Maurillo, L; Panetta, P; Suppo, G; Venditti, A | 1 |
| Boyd, RL; Clyde, J; Halbherr, T; Millenson, MM; Morris, GJ; Padavic-Shaller, K; Rogatko, A; Schilder, RJ; Smith, MR; Wang, H; Yeslow, G | 1 |
| Beltrami, G; Carella, AM; Corsetti, MT; Musto, P; Scalzulli, P | 1 |
| Bellas, C; Catovsky, D; Matutes, E; Pocock, C; Santon, A; Shah, G; Thornton, PD; Wotherspoon, AC | 1 |
| Albitar, M; Beran, M; Cortes, J; Do, KA; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Koller, C; Lerner, S; O'Brien, S; Thomas, D; Wen, S; Wierda, W | 1 |
| Abati, A; Berman, DM; Dudley, ME; Filie, AC; Gea-Banacloche, J; Gracia, GJ; Jones, SA; Kammula, U; Mangiameli, DP; Mavroukakis, SA; Pelletier, MM; Restifo, NP; Robinson, MR; Rogers, LJ; Rosenberg, SA; Royal, RE; Sherry, RM; Topalian, SL; White, DE; Wunderlich, JR; Yang, JC | 1 |
| Coiffier, B; Michallet, AS; Michallet, M; Salles, G | 1 |
| Richards, S | 1 |
| Amin, CJ; Rabinowitz, I | 1 |
| Berdel, WE; Berning, B; Beyer, J; Bornhauser, M; Buchner, T; Ehninger, G; Fauser, AA; Heinecke, A; Kienast, J; Kroger, M; Neubauer, A; Sauerland, MC; Scheffold, C; Silling, G; Stelljes, M | 1 |
| Claxton, DF; Ehmann, C; Rybka, W | 1 |
| Chaleteix, C; Choquet, S; Christian, B; Delmer, A; Dreyfus, F; Fermand, JP; Grange, MJ; Leblond, V; Lévy, V; Morel, P; Stalniewicz, L; Tamburini, J | 1 |
| Irving, I; Kennedy, GA; McCarthy, C; Perel, JM; Walker, O; Williams, B | 1 |
| Blau, IW; Fietz, T; Gentilini, C; Glass, B; Marinets, O; Muessig, A; Munz, DL; Rieger, K; Sandrock, D; Thiel, E; Uharek, L | 1 |
| Byrd, JC; Caligiuri, MA; Grever, MR; Gribben, JG; Heerema, NA; Lampson, B; Larson, RA; Lozanski, G; Lucas, DM; Peterson, BL | 1 |
| Ikeda, Y; Murase, T; Nishida, H; Park, JW; Ueno, H; Yano, T | 1 |
| Chiusolo, P; De Padua, L; Efremov, DG; Garzia, M; Laurenti, L; Leone, G; Piccioni, P; Piccirillo, N; Sica, S; Tarnani, M | 1 |
| Ijichi, O; Ikarimoto, N; Ishikawa, S; Kawano, Y; Kodama, Y; Manago, K; Nishikawa, T; Okamoto, Y; Shinkoda, Y; Tanabe, T | 1 |
| Croce, C | 1 |
| Emmons, RV; Jillella, AP; Klumpp, TR; Mangan, KF; Shafer, D | 1 |
| Albitar, M; Day, A; Do, KA; Estey, E; Giles, FJ; Jilani, I; Johnson, M; Kantarjian, H; Keating, M; O'brien, S; Pierce, S; Verstovsek, S | 1 |
| Gadre, SA; Ge, Y; Lockhart, LH; Northup, JK; Velagaleti, GV | 1 |
| Chuhjo, T; Kondo, Y; Kotani, T; Nakao, S; Ohtake, S; Okumura, H; Ozaki, J; Sugimori, C; Sugimori, N; Takami, A; Ueda, M; Yamaguchi, M; Yamazaki, H | 1 |
| Arceci, RJ; Chen, AR; Colombani, P; Higman, MA; Schwartz, CL; Wharam, M; Williams, KM | 1 |
| Bay, JO; Bertuzzi, A; Carrabba, MG; Castagna, L; Corradini, P; Demirer, T; Grosso, F; Niederwieser, D; Pedrazzoli, P; Secondino, S; Siena, S; Spina, F | 1 |
| Anagnostopoulos, A; Anderlini, P; Carrasco-Yalan, A; Champlin, RE; Couriel, D; de Lima, M; de Meis, E; Donato, M; Ghosh, S; Giralt, S; Hosing, C; Kebriaei, P; Khouri, I; Oran, B; Popat, U; Qazilbash, M; Saliba, R | 1 |
| Brugiatelli, M; Federico, M; Liberati, M; Marcheselli, R; Merli, F; Orsucci, L; Pozzi, S; Sacchi, S; Tucci, A; Vallisa, D | 1 |
| Celsing, F; Choudhury, A; Derkow, K; Jondal, M; Norberg, M; Okvist, A; Olsson, A; Osorio, LM; Osterborg, A; Rosenquist, R; Tobin, G | 1 |
| Catovsky, D; Dearden, C; Else, M; Hamblin, T; Milligan, D; Richards, S; Wade, R | 1 |
| Christian, BA; Lin, TS | 1 |
| Amabile, M; Arpinati, M; Farabegoli, P; Martinelli, G; Testoni, N; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL; Zuffa, E | 1 |
| Gjedde, SB; Hansen, MM | 1 |
| Beran, M; Estey, E; Freireich, EJ; Kantarjian, H; Keating, MJ; Koller, C; Lerner, S; O'Brien, S; Robertson, LE | 1 |
| Curti, A; Lemoli, RM; Leopardi, G; Motta, MR; Rizzi, S; Testoni, N; Tura, S; Visani, G | 1 |
| Demeter, J; Lehoczky, D; Varga, F | 1 |
| Battista, R; Bendandi, M; Cellini, C; Ciccone, F; De Renzo, A; Gentilini, P; Gherlinzoni, F; Gobbi, M; Guardigni, L; Lauta, VM; Magagnoli, M; Marra, R; Mazza, P; Moretti, L; Ricciuti, F; Ronconi, F; Stefoni, V; Tura, S; Zaccaria, A; Zinzani, PL | 1 |
| Gabeeva, NG; Kaplanskaia, IB; Kremenetskaia, AM; Moiseeva, TN; Pivnik, AV; Samoĭlova, RS; Varlamova, EIu; Zybunova, EE | 1 |
| Bambara, LM; Biasi, D; Caramaschi, P; Carletto, A | 1 |
| Beran, M; Cortes, J; Giles, FJ; Kantarjian, HM; Keating, M; Koller, CA; Lerner, S; O'Brien, SM | 1 |
| Brandt, L; Glimelius, B; Kimby, E; Nygren, P | 1 |
| Blume, KG; Chauncey, T; Feinstein, L; Flowers, C; Georges, G; Kiem, HP; Little, MT; Maloney, D; Maris, M; McSweeney, PA; Nash, RA; Niederwieser, D; Radich, J; Sandmaier, B; Shizuru, J; Storb, R; Woolfrey, A; Zaucha, JM | 1 |
| Czuczman, MS | 1 |
| Cazin, B; Chevret, S; Fermand, JP; Guibon, O; Harousseau, JL; Leblond, V; Lévy, V; Maloisel, F; Porcher, R; Remenieras, L | 1 |
| Alimena, G; Breccia, M; Carmosino, I; D'Andrea, M; D'Elia, GM; Petti, MC | 1 |
| Goldschmidt, H; Görner, M; Ho, AD; Kordelas, L; Luft, T; Moos, M; Pfeiffer, S; Punzel, M; Thalheimer, M; Ustaoglu, F; Weber-Nordt, R | 1 |
15 review(s) available for vidarabine and Disease Exacerbation
| Article | Year |
|---|---|
Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 12; Cyclin D1; Cyclophosphamide; Disease Progression; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Rituximab; Treatment Outcome; Trisomy; Vidarabine | 2018 |
[Hemophagocytic lymphohistiocytosis].
Topics: Antibodies, Monoclonal, Murine-Derived; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Disease Progression; Doxorubicin; Drug Therapy, Combination; Etoposide; Hematopoietic Stem Cell Transplantation; Humans; Lymphohistiocytosis, Hemophagocytic; Methotrexate; Multiple Organ Failure; Prednisolone; Prednisone; Rituximab; Severity of Illness Index; Transplantation Conditioning; Vidarabine; Vincristine | 2014 |
Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Clinical Trials as Topic; Consensus Development Conferences as Topic; Disease Progression; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Nitrogen Mustard Compounds; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2014 |
Richter syndrome: an aggressive transformation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clone Cells; Cyclophosphamide; Disease Progression; Doxorubicin; Hospice and Palliative Care Nursing; Humans; Hypercalcemia; L-Lactate Dehydrogenase; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphoma, Large B-Cell, Diffuse; Male; Neoplastic Stem Cells; Organoplatinum Compounds; Palliative Care; Prednisone; Prognosis; Risk Factors; Rituximab; Salvage Therapy; Syndrome; Vidarabine; Vincristine | 2015 |
Antiviral agents for treatment of herpes simplex virus infection in neonates.
Topics: Acyclovir; Antiviral Agents; Developmental Disabilities; Disease Progression; Herpes Simplex; Humans; Infant, Newborn; Randomized Controlled Trials as Topic; Vidarabine | 2009 |
Determinants of the optimal first-line therapy for follicular lymphoma: a decision analysis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Decision Support Techniques; Disease Progression; Disease-Free Survival; Doxorubicin; Humans; Immunotherapy; Lymphoma, Follicular; Markov Chains; Prednisone; Quality-Adjusted Life Years; Rituximab; Vidarabine; Vincristine | 2010 |
Chemoimmunotherapy of chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Disease Progression; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Rituximab; Treatment Failure; Vidarabine | 2010 |
Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Topics: Animals; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Male; Mice; Rituximab; Vidarabine | 2010 |
Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autoimmune Diseases; Bleomycin; Bone Marrow; Bone Marrow Diseases; Chemotherapy, Adjuvant; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Paraproteins; Prednisone; Prognosis; Remission Induction; Retrospective Studies; Splenectomy; Splenic Neoplasms; Survival Analysis; Treatment Outcome; Vidarabine; Vincristine | 2002 |
[News in therapeutic management of chronic lymphoid leukemia].
Topics: Age Factors; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Vidarabine | 2005 |
Fludarabine increases complete response but not survival compared with conventional alkylator-based regimens for previously untreated chronic lymphocytic leukaemia.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vidarabine | 2005 |
Antibody therapy for chronic lymphocytic leukemia.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drugs, Investigational; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mutation; Pentostatin; Rituximab; Vidarabine | 2008 |
A systematic overview of chemotherapy effects in B-cell chronic lymphocytic leukaemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Humans; Leukemia, B-Cell; Prednisolone; Prognosis; Recurrence; Risk Factors; Salvage Therapy; Vidarabine; Vincristine | 2001 |
Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
Topics: Adult; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclosporine; Disease Progression; Dogs; Forecasting; Graft Enhancement, Immunologic; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunosuppressive Agents; Lymphocyte Transfusion; Methotrexate; Middle Aged; Mycophenolic Acid; Neoplasms; Prednisone; Radiation Chimera; T-Lymphocytes, Cytotoxic; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2001 |
Combination chemotherapy and rituximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Disease Progression; Doxorubicin; Flow Cytometry; Humans; Immunotherapy; Lymphoma, Non-Hodgkin; Prednisolone; Proto-Oncogene Proteins c-bcl-2; Rituximab; Time Factors; Translocation, Genetic; Treatment Outcome; Vidarabine; Vincristine | 2001 |
36 trial(s) available for vidarabine and Disease Exacerbation
| Article | Year |
|---|---|
Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
Topics: Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Female; Gene Expression Profiling; Germany; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Predictive Value of Tests; Remission Induction; Risk Assessment; Risk Factors; Rituximab; Texas; Time Factors; Transcriptome; Treatment Outcome; Vidarabine | 2019 |
A phase II Japanese trial of fludarabine, cyclophosphamide and rituximab for previously untreated chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclophosphamide; Disease Progression; Endpoint Determination; Female; Humans; Immunosuppression Therapy; Japan; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Rituximab; Treatment Outcome; Vidarabine | 2021 |
A Randomized Study Comparing Stem Cell Transplantation Versus Conventional Therapy for Low- and Intermediate-Risk Myelodysplastic Syndromes Patients.
Topics: Adult; Busulfan; Cyclophosphamide; Disease Progression; Factor Analysis, Statistical; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myelodysplastic Syndromes; Opportunistic Infections; Prognosis; Quality of Life; Risk Factors; Stem Cell Transplantation; Transplantation, Homologous; Vidarabine; Young Adult | 2017 |
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Recurrence; Rituximab; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
Donor-derived natural killer cells infused after human leukocyte antigen-haploidentical hematopoietic cell transplantation: a dose-escalation study.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Child; Disease Progression; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Killer Cells, Natural; Lymphocyte Count; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2014 |
Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Maintenance Chemotherapy; Male; Middle Aged; Retreatment; Vidarabine | 2015 |
Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chromosome Aberrations; Combined Modality Therapy; Disease Progression; Female; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Neoplasm Staging; Pyrroles; Recurrence; Retreatment; Rituximab; Treatment Outcome; Vidarabine | 2015 |
Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Rituximab; Survival Rate; Treatment Outcome; Vidarabine | 2015 |
The long-term outcome of patients in the LRF CLL4 trial: the effect of salvage treatment and biological markers in those surviving 10 years.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chlorambucil; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Remission Induction; Salvage Therapy; Treatment Outcome; Vidarabine | 2016 |
A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Male; Middle Aged; Survival Analysis; Thalidomide; Vidarabine | 2016 |
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, CD20; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CD52 Antigen; Cyclophosphamide; Disease Progression; Epidemiologic Methods; Female; Glycoproteins; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Prognosis; Rituximab; Vidarabine | 2010 |
Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Male; Melphalan; Methotrexate; Middle Aged; Mycosis Fungoides; Myeloablative Agonists; Recurrence; Sezary Syndrome; Tacrolimus; Time Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2010 |
[Evaluation of fludarabine-containing regimens versus immunochemotherapy for chronic lymphocytic leukemia].
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Immunologic Factors; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Mitoxantrone; Myeloablative Agonists; Remission Induction; Retrospective Studies; Rituximab; Treatment Outcome; Vidarabine | 2010 |
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Immunologic Factors; Incidence; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukopenia; Male; Middle Aged; Neutropenia; Rituximab; Severity of Illness Index; Treatment Outcome; Vidarabine | 2010 |
Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm, Residual; Prognosis; Prospective Studies; Rituximab; Survival Rate; Vidarabine | 2012 |
Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
Topics: Adult; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Cytarabine; Dexamethasone; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm, Residual; Peripheral Blood Stem Cell Transplantation; Prednisolone; Prospective Studies; Recurrence; Risk; Rituximab; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Vincristine; Whole-Body Irradiation | 2013 |
Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
Topics: Aged; Alleles; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; Chlorambucil; Cyclophosphamide; Disease Progression; Disease-Free Survival; DNA-Binding Proteins; Female; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Gene Silencing; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Protein Serine-Threonine Kinases; Survival Analysis; Tumor Suppressor Proteins; United Kingdom; Vidarabine | 2012 |
Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dexamethasone; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Survival Analysis; Time Factors; Vidarabine | 2002 |
Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.
Topics: Aged; Aged, 80 and over; Cyclophosphamide; Disease Progression; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Survival Analysis; Time Factors; Vidarabine; Waldenstrom Macroglobulinemia | 2003 |
Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Disease Progression; Drug Administration Schedule; Female; Humans; Interferon-alpha; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neoplasms, Second Primary; Prednisone; Prognosis; Remission Induction; Survival Analysis; Treatment Outcome; Vidarabine | 2003 |
High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Disease Progression; Drug Therapy; Female; Graft vs Tumor Effect; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prognosis; Prospective Studies; Recurrence; Remission Induction; Risk; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
Phase II study of fludarabine and alpha-interferon in patients with low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Administration Schedule; Fatigue; Female; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Interferon alpha-2; Interferon-alpha; Life Tables; Lymphoma, Non-Hodgkin; Male; Middle Aged; Proportional Hazards Models; Recombinant Proteins; Survival Analysis; Treatment Outcome; Vidarabine | 2004 |
A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Infections; Male; Melphalan; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Remission Induction; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Topics: Adolescent; Adoptive Transfer; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Cyclophosphamide; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Interleukin-2; Lymphocytes, Tumor-Infiltrating; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Treatment Outcome; Vidarabine | 2005 |
Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia.
Topics: Adult; Aged; Disease Progression; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2005 |
Low-dose thalidomide in combination with oral fludarabine and cyclophosphamide is ineffective in heavily pre-treated patients with chronic lymphocytic leukemia.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Thalidomide; Treatment Failure; Tumor Necrosis Factor-alpha; Vidarabine | 2007 |
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myelodysplastic Syndromes; Risk Factors; Survivors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Gene Rearrangement; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Polymerase Chain Reaction; Proto-Oncogene Proteins c-bcl-2; Rituximab; Thrombocytopenia; Time Factors; Treatment Outcome; Vidarabine | 2007 |
The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Coombs Test; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Survival Analysis; Treatment Outcome; Vidarabine | 2008 |
Salvage therapy with fludarabine in patients with progressive B-chronic lymphocytic leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Vidarabine | 1996 |
Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CD4 Lymphocyte Count; Disease Progression; Disease-Free Survival; Female; Fever; Follow-Up Studies; Hodgkin Disease; Humans; Incidence; Infections; Leukemia, Lymphocytic, Chronic, B-Cell; Life Tables; Male; Middle Aged; Neoplasms, Second Primary; Prednisolone; Remission Induction; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 1998 |
Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Disease Progression; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Lymphocytic, Chronic, B-Cell; Linear Models; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Neoplasm Staging; Remission Induction; Survival Rate; Vidarabine | 2000 |
Unsuccessful treatment with fludarabine in four cases of refractory rheumatoid arthritis.
Topics: Arthritis, Rheumatoid; Disease Progression; Female; Humans; Immunosuppressive Agents; Lymphocyte Count; Male; Middle Aged; Prednisone; Treatment Failure; Vidarabine | 2000 |
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Flow Cytometry; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Salvage Therapy; Treatment Outcome; Vidarabine | 2001 |
Evaluating treatment strategies in advanced Waldenström macroglobulinemia: use of quality-adjusted survival analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Health Status Indicators; Humans; Prednisone; Quality of Life; Retrospective Studies; Survival Rate; Vidarabine; Waldenstrom Macroglobulinemia | 2001 |
69 other study(ies) available for vidarabine and Disease Exacerbation
| Article | Year |
|---|---|
Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome using treosulfan based compared to other reduced-intensity or myeloablative conditioning regimens. A report of the chronic malignancies working party of the EBMT.
Topics: Adolescent; Adult; Aged; Allografts; Busulfan; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Recurrence; Registries; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2021 |
DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy.
Topics: Adult; Aged; Cyclophosphamide; Disease Progression; DNA Methylation; Epigenesis, Genetic; Female; Gene Regulatory Networks; High-Throughput Nucleotide Sequencing; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Longitudinal Studies; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Rituximab; Treatment Outcome; Vidarabine | 2019 |
Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Topics: Antibodies, Viral; B-Cell Maturation Antigen; Cough; COVID-19; COVID-19 Nucleic Acid Testing; COVID-19 Serological Testing; Cyclophosphamide; Disease Progression; Fever; Hospitalization; Humans; Immunosuppressive Agents; Immunotherapy, Adoptive; Male; Middle Aged; Multiple Myeloma; Receptors, Chimeric Antigen; SARS-CoV-2; Vidarabine | 2021 |
DNA polymerase ν gene expression influences fludarabine resistance in chronic lymphocytic leukemia independently of p53 status.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Progression; DNA-Directed DNA Polymerase; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Mutation; Prognosis; Proportional Hazards Models; Tumor Suppressor Protein p53; Vidarabine | 2018 |
Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Disease Progression; Female; Humans; Male; Middle Aged; Prognosis; Proportional Hazards Models; Risk Factors; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2018 |
Downregulating STAT1/caspase-3 signaling with fludarabine to alleviate progression in a rat model of steroid-induced avascular necrosis of the femoral head.
Topics: Animals; Caspase 3; Dexamethasone; Disease Models, Animal; Disease Progression; Down-Regulation; Femur Head; Femur Head Necrosis; Male; Rats, Sprague-Dawley; Signal Transduction; STAT1 Transcription Factor; Vidarabine | 2019 |
Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximab.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prognosis; Rituximab; Treatment Outcome; Vidarabine | 2013 |
National Institutes of Health classification for chronic graft-versus-host disease predicts outcome of allo-hematopoietic stem cell transplant after fludarabine-busulfan-antithymocyte globulin conditioning regimen.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoprevention; Chronic Disease; Disease Progression; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Recurrence; Severity of Illness Index; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2014 |
Donor cell-derived myelodysplastic syndrome with ring chromosome 7 after allogeneic hematopoietic stem cell transplant in 2 patients with lymphomas as primary disease.
Topics: Allografts; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Biomarkers, Tumor; Bone Marrow; Cell Transformation, Neoplastic; Chromosome Deletion; Chromosomes, Human, Pair 7; Cyclophosphamide; Disease Progression; ETS Translocation Variant 6 Protein; Female; Gene Deletion; Humans; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Living Donors; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Peripheral Blood Stem Cell Transplantation; Proto-Oncogene Proteins c-ets; Repressor Proteins; Ring Chromosomes; Rituximab; Transplantation Chimera; Vidarabine | 2014 |
[Neoplastic mastocytosis evolving from a poor prognosis acute myeloid leukemia].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Fatal Outcome; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunophenotyping; Leukemia, Mast-Cell; Leukemia, Myeloid, Acute; Mast Cells; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Prognosis; Vidarabine | 2015 |
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab).
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Rituximab; Salvage Therapy; Survival Analysis; Treatment Outcome; Vidarabine | 2014 |
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Gene Expression Regulation, Leukemic; Humans; Immunotherapy; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; MicroRNAs; Multivariate Analysis; Piperidines; Protein-Tyrosine Kinases; Pyrazoles; Pyrimidines; Rituximab; Treatment Outcome; Vidarabine | 2015 |
Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Calreticulin; Combined Modality Therapy; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Disease Progression; Female; Graft Survival; Humans; Janus Kinase 2; Male; Melphalan; Middle Aged; Myeloablative Agonists; Neutrophils; Peripheral Blood Stem Cell Transplantation; Polycythemia Vera; Primary Myelofibrosis; Receptors, Thrombopoietin; Retrospective Studies; Thrombocythemia, Essential; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation; Young Adult | 2015 |
Inhibition of integrin β1 decreases the malignancy of ovarian cancer cells and potentiates anticancer therapy via the FAK/STAT1 signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Bevacizumab; Cell Adhesion; Cell Line, Tumor; Cell Movement; Disease Progression; Drug Synergism; Female; Focal Adhesion Kinase 1; Gene Expression Regulation, Neoplastic; Humans; Integrin beta1; Neoplasm Invasiveness; Ovarian Neoplasms; Signal Transduction; Vidarabine | 2015 |
A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemotherapy, Adjuvant; Child; Child, Preschool; Cyclophosphamide; Cytarabine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infant; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Proportional Hazards Models; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Transplantation, Haploidentical; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Maximum Tolerated Dose; Methylprednisolone; Middle Aged; Myeloablative Agonists; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine | 2008 |
Monitoring for cytomegalovirus and Epstein-Barr virus infection in chronic lymphocytic leukemia patients receiving i.v. fludarabine-cyclophosphamide combination and alemtuzumab as consolidation therapy.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Cytomegalovirus Infections; Diagnosis, Differential; Disease Progression; Epstein-Barr Virus Infections; Female; Genome, Viral; Herpesvirus 4, Human; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Monitoring, Physiologic; Vidarabine | 2008 |
Assessment of peripheral blood and bone marrow cells apoptosis caused by purine analogues in patients with chronic lymphocytic leukemia in correlation with parameters of disease progression.
Topics: ADP-ribosyl Cyclase 1; Antineoplastic Agents; Apoptosis; B-Lymphocyte Subsets; bcl-2-Associated X Protein; Biomarkers; Bone Marrow Cells; Caspase 3; Chronic Disease; Cladribine; Disease Progression; Enzyme Activation; Humans; Leukemia, Lymphoid; Membrane Glycoproteins; Prognosis; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2010 |
High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Methylprednisolone; Middle Aged; Remission Induction; Treatment Outcome; Vidarabine | 2010 |
Chronic lymphocytic leukaemia--moving towards cure?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosome Deletion; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 13; Chromosomes, Human, Pair 17; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Humans; Immunologic Factors; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Prognosis; Randomized Controlled Trials as Topic; Remission Induction; Rituximab; Time Factors; Treatment Outcome; Vidarabine | 2010 |
Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2011 |
Early initial therapy of advanced follicular lymphoma: the need for vigilance.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Follow-Up Studies; Humans; Lymphoma, Follicular; Neoadjuvant Therapy; Population Surveillance; Rituximab; Vidarabine | 2011 |
Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Disease-Free Survival; Female; Humans; International Classification of Diseases; Male; Middle Aged; Prognosis; Recurrence; Rituximab; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2011 |
Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness.
Topics: Amino Acid Sequence; Antineoplastic Agents; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; In Situ Hybridization, Fluorescence; Karyotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Sequence Data; Mutation; Oligonucleotide Array Sequence Analysis; Phosphoproteins; Polymorphism, Single Nucleotide; Ribonucleoprotein, U2 Small Nuclear; RNA Splicing Factors; Sequence Homology, Amino Acid; Spliceosomes; Tumor Suppressor Protein p53; Vidarabine | 2011 |
Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.
Topics: Age Factors; Aged; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Radiation Dosage; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2011 |
Splenic re-irradiation for waldenstrőm's macroglobulinemia.
Topics: Aged; Antineoplastic Agents; Chlorambucil; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Humans; Radiotherapy, Conformal; Spleen; Thalidomide; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cohort Studies; Cyclophosphamide; Disease Progression; Disease-Free Survival; Genetic Predisposition to Disease; Humans; Middle Aged; Pyrazines; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2012 |
Distal acquired demyelinating symmetric polyneuropathy progressing to classic chronic inflammatory demyelinating polyneuropathy and response to fludarabine and cyclophosphamide.
Topics: Cyclophosphamide; Disease Progression; Female; Humans; Immunosuppressive Agents; Middle Aged; Neural Conduction; Peripheral Nerves; Polyneuropathies; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Treatment Outcome; Vidarabine | 2013 |
Exacerbation of lymphomatoid papulosis during rituximab therapy.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Doxorubicin; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphomatoid Papulosis; Male; Middle Aged; Prednisolone; Rituximab; Vidarabine; Vincristine | 2014 |
Long-term follow-up of patients with CLL treated with allogeneic hematopoietic transplantation.
Topics: Adult; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Recurrence; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine; Cohort Studies; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Life Tables; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Podophyllotoxin; Proportional Hazards Models; Salvage Therapy; Survival Analysis; Survival Rate; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2002 |
Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes.
Topics: Antineoplastic Agents; Bayes Theorem; Benzamides; Bone Marrow Transplantation; Busulfan; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Imatinib Mesylate; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Research Design; Sarcoma; Treatment Outcome; Vidarabine | 2003 |
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen.
Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progression; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Histocompatibility; Humans; Immunosuppressive Agents; Incidence; Life Tables; Lymphocyte Transfusion; Male; Middle Aged; Neoplasms; Peripheral Blood Stem Cell Transplantation; Recurrence; Risk Factors; Siblings; Survival Analysis; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2003 |
Remission of follicular non-Hodgkin's lymphoma with denileukin diftitox (ONTAK) after progression during rituximab, CHOP and fludarabine therapy.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Diphtheria Toxin; Disease Progression; Doxorubicin; Humans; Interleukin-2; Lymphoma, Non-Hodgkin; Male; Peripheral Blood Stem Cell Transplantation; Prednisone; Recombinant Fusion Proteins; Remission Induction; Rituximab; Time Factors; Vidarabine; Vincristine | 2003 |
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease; Disease Progression; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Siblings; Stem Cell Transplantation; Survival Analysis; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia.
Topics: Aged; Antineoplastic Agents; Case-Control Studies; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Frequency; Genes, bcl-2; Genetic Predisposition to Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Polymorphism, Genetic; Receptors, Purinergic P2; Receptors, Purinergic P2X7; Vidarabine | 2003 |
Allogeneic peripheral blood stem cell transplantation following fludarabine-based conditioning in six children with advanced Hodgkin's disease.
Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Female; Graft vs Host Disease; Hodgkin Disease; Humans; Immunosuppressive Agents; Male; Melphalan; Neoplasm Recurrence, Local; Peripheral Blood Stem Cell Transplantation; Remission Induction; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2004 |
[Allogeneic stem cell transplantation following non-myeloablative conditioning: favorable results in 21 high risk patients with hematological malignancies treated in the Utrecht University Medical Center, the Netherlands].
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Prospective Studies; Remission Induction; Risk Factors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2003 |
45th annual meeting of the American Society of Hematology. December 6-9, 2003, San Diego, California.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Diphtheria Toxin; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Hodgkin Disease; Humans; Interleukin-2; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Male; Middle Aged; Prednisone; Recombinant Fusion Proteins; Retrospective Studies; Rituximab; Time Factors; Treatment Outcome; Vidarabine; Vincristine | 2003 |
Variant Richter's syndrome: a rare case of classical Hodgkin's lymphoma developing in a patient with chronic lymphocytic leukemia treated with fludarabine.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Biopsy; Bone Marrow; Cyclophosphamide; Disease Progression; Hodgkin Disease; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Second Primary; Syndrome; Time Factors; Vidarabine | 2003 |
Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Retrospective Studies; Rituximab; Survival Rate; Time Factors; Treatment Outcome; Vidarabine | 2005 |
Fludarabine as the possible cause of acute myelofibrosis.
Topics: Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Primary Myelofibrosis; Vidarabine | 2004 |
Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Topics: Adolescent; Adult; Age Factors; Aged; Child; Chimera; Disease Progression; Female; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Kinetics; Male; Middle Aged; Recurrence; Survival Rate; T-Lymphocytes; Tissue Donors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Acute tumour lysis syndrome after oral fludarabine in a patient with chronic lymphocytic leukaemia.
Topics: Acute Kidney Injury; Administration, Oral; Disease Progression; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Tumor Lysis Syndrome; Vidarabine | 2004 |
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia.
Topics: ADP-ribosyl Cyclase 1; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Burkitt Lymphoma; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Gene Rearrangement, B-Lymphocyte, Heavy Chain; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Immunophenotyping; In Situ Hybridization, Fluorescence; Interphase; Life Tables; Male; Middle Aged; Neoplasm Proteins; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Solubility; Tumor Suppressor Protein p53; Vidarabine; ZAP-70 Protein-Tyrosine Kinase | 2004 |
Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Disease Progression; Female; Herpesvirus 4, Human; Humans; Kidney; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Nodes; Male; Middle Aged; Reed-Sternberg Cells; Treatment Outcome; Tumor Suppressor Protein p53; Vidarabine | 2005 |
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Cyclophosphamide; Disease Progression; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Proportional Hazards Models; Recurrence; Remission Induction; Rituximab; Survival Analysis; Treatment Outcome; Vidarabine | 2005 |
An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Disease Progression; Female; Humans; Pleural Effusion; Recurrence; Rituximab; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Cyclophosphamide; Disease Progression; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Middle Aged; Sirolimus; Survival Analysis; Treatment Outcome; Vidarabine | 2005 |
Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Female; Hemoglobins; Humans; Immunoglobulin M; Male; Middle Aged; Prognosis; Retrospective Studies; Survival Rate; Time Factors; Treatment Outcome; Vidarabine; Waldenstrom Macroglobulinemia | 2005 |
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Clone Cells; Cytarabine; Disease Progression; Fatal Outcome; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic; Vidarabine | 2005 |
Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan.
Topics: Adult; Antibodies, Monoclonal; Antineoplastic Agents; Cyclophosphamide; Disease Progression; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Male; Radioimmunotherapy; Recurrence; Remission Induction; Retrospective Studies; Time Factors; Transplantation Conditioning; Treatment Outcome; Vidarabine; Yttrium Radioisotopes | 2006 |
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 17; Clinical Trials, Phase II as Topic; Disease Progression; Disease-Free Survival; Female; Gene Deletion; Genes, Immunoglobulin Heavy Chain; Genetic Predisposition to Disease; Humans; Immunologic Factors; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Rituximab; Tumor Suppressor Protein p53; Vidarabine | 2006 |
Fludarabine-associated autoimmune hemolytic anemia occurring in B-cell chronic lymphocytic leukemia.
Topics: Aged, 80 and over; Anemia, Hemolytic, Autoimmune; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Disease Progression; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Prednisolone; Remission Induction; Risk Factors; Rituximab; Treatment Outcome; Vidarabine | 2006 |
Rapid progression of metastatic osteosarcoma after initiation of a reduced-intensity conditioning regimen with immunosuppressive fludarabine.
Topics: Antineoplastic Agents; Bone Neoplasms; Child; Disease Progression; Fatal Outcome; Female; Humans; Immunosuppression Therapy; Magnetic Resonance Imaging; Myeloablative Agonists; Osteosarcoma; Pleural Neoplasms; Radiography, Thoracic; Vidarabine | 2006 |
MicroRNAs in leukemia.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Disease Progression; Flavonoids; Gene Expression Regulation, Leukemic; Humans; Leukemia; Mice; MicroRNAs; Piperidines; Prognosis; Vidarabine | 2006 |
Mixed chimerism and graft failure following conditioning with the fludarabine and cyclophosphamide nonablative regimen; conversion to full donor chimerism.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chimerism; Chronic Disease; Cohort Studies; Cyclophosphamide; Disease Progression; Female; Follow-Up Studies; Graft Rejection; Graft vs Host Disease; Hematologic Neoplasms; Humans; Injections, Intravenous; Lymphocyte Transfusion; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Tissue Donors; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2007 |
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarkers, Tumor; Cytarabine; Disease Progression; Female; HLA Antigens; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Proteins; Predictive Value of Tests; Proportional Hazards Models; Remission Induction; Solubility; Topotecan; Treatment Outcome; Vidarabine | 2007 |
Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition?
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Burkitt Lymphoma; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 14; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 8; Chromosomes, Human, X; Clone Cells; Cyclophosphamide; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; Female; Genes, myc; Humans; Karyotyping; Lymph Nodes; Lymphoma, AIDS-Related; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Mutagenesis, Insertional; Pleural Effusion, Malignant; Prednisone; Rituximab; Translocation, Genetic; Trisomy; Vidarabine; Vincristine | 2007 |
Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Blast Crisis; Chimera; Cord Blood Stem Cell Transplantation; Disease Progression; Fatal Outcome; Female; Graft Rejection; Graft vs Host Disease; Histocompatibility; HLA Antigens; Humans; Immunity, Maternally-Acquired; Isoantigens; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Siblings; Tissue Donors; Transplantation Conditioning; Vidarabine | 2007 |
Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma.
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biliary Atresia; Carboplatin; Carmustine; Cyclophosphamide; Cytarabine; Disease Progression; Doxorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Immunocompromised Host; Immunosuppressive Agents; Liver Transplantation; Lymphoma, T-Cell, Peripheral; Lymphoproliferative Disorders; Melphalan; Mesna; Postoperative Complications; Prednisone; Radiotherapy, Adjuvant; Transplantation, Autologous; Vidarabine; Vincristine | 2008 |
Reduced intensity stem cell transplantation for advanced soft tissue sarcomas in adults: a retrospective analysis of the European Group for Blood and Marrow Transplantation.
Topics: Adult; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Europe; Female; Follow-Up Studies; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prognosis; Registries; Remission Induction; Retrospective Studies; Sarcoma; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2007 |
Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Minor Histocompatibility Antigens; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation; Vidarabine | 2007 |
FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Bone Marrow Transplantation; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Remission Induction; Vidarabine | 1996 |
Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Agents; Bone Marrow Purging; Busulfan; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease Progression; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Length of Stay; Leukemia, Myeloid; Male; Mechlorethamine; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Neoplastic Stem Cells; Pilot Projects; Platelet Transfusion; Recurrence; Remission Induction; Risk; Salvage Therapy; Survival Analysis; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine | 1999 |
[Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
Topics: Adult; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Female; Follow-Up Studies; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukocyte Count; Male; Middle Aged; Treatment Outcome; Vidarabine | 1999 |
[Fludarabine treatment of chronic lymphoid leukemia].
Topics: Adult; Antineoplastic Agents; Bone Marrow; Disease Progression; Female; Humans; Injections, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Remission Induction; Retrospective Studies; Vidarabine | 2000 |
Cutaneous pleomorphic T-cell lymphoma coexisting with myelodysplastic syndrome transforming into acute myeloid leukemia: successful treatment with a fludarabine-containing regimen.
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Contraindications; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Immunophenotyping; Leukemia, Myeloid, Acute; Lymphoma, T-Cell, Cutaneous; Male; Methotrexate; Neoplasms, Second Primary; Remission Induction; Skin Neoplasms; Vidarabine | 2002 |
Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine.
Topics: Adult; Cohort Studies; Disease Progression; Feasibility Studies; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Depletion; Lymphocyte Transfusion; Male; Middle Aged; Recurrence; Retrospective Studies; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2002 |